– USA, MA – BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the addition of Kenin Spivak to its Board as an Independent Director.
About Kenin M. Spivak
Mr. Spivak is the founder, chairman, and CEO of SMI Group LLC and chairman of its operating units. Before SMI Group, Mr. Spivak led multi-national companies with billions of dollars of worldwide sales and operations in more than 30 countries, including serving as CEO of a News Corporation affiliate, a wireless technology company, and distribution companies, principal operating officer of major studio MGM/UA, founding chairman of the Paul Mitchell cosmetology schools, and an officer and director of Merrill Lynch media and entertainment partnerships. He has served as a director of, and advisor to, several healthcare and technology companies.
“BPGbio is greatly accelerating the development of new therapeutics and diagnostics by uniting its pioneering scientific team, the nation’s leading biobank, and cutting-edge AI capabilities,” said Kenin Spivak. “I am honored to join the board and look forward to supporting BPG’s development and commercialization of its late-stage assets.”
Mr. Spivak received A.B., M.B.A., and J.D. degrees from Columbia University, each with honors, completing all three degrees in six years. He is admitted to practice law in California and New York and holds numerous securities licenses, including Series 24 (general securities principal).
About BPGbio, Inc.
BPGbio is the leading biology-first AI-powered clinical-stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world’s largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way disease is diagnosed and treated.
BPGbio’s therapeutic pipeline, developed from the company’s NAi Interrogative Biology Platform, includes therapeutic candidates being studied for glioblastoma multiforme in active phase 2b, pancreatic cancer in phase 2a, epidermolysis bullosa, squamous cell carcinoma, sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson’s disease, and diabetes type II. The company’s diagnostic pipeline includes its prostate diagnostic panel pstateDx, as well as tests being developed and validated for the detection of Parkinson’s disease, pancreatic cancer, breast cancer, and liver disease.
For more information: https://bpgbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
